The Service of the Commission for the Protection of Competition on the 10th of November 2008 received on behalf of the company Ivytan AB notification of a proposed concentration according to Article 13 of the Control of Concentration between Enterprises Law (Number 22(I)/99), concerning an agreement by which Ivytan AB will proceed to a public offer in order to acquire 100% of the issued share capital of the company Q-Med AB.
” Ivytan AB” is a new enterprises whose only aim to acquire all of Q-Med AB´s share capital.
“Q-Med AB” operations concentrate in the medical sector with the development, construction and sale of implants και other goods to be used in hospitals.
On the 5th of December 2008, the Commission for the Protection of Competition, based on the findings of the preliminary investigation of the notified concentration that the Service conducted and submitted to the C.P.C., and acting on the basis of the Law in force, concluded that, even though the concentration comes within the ambit of the law, it does not raise serious doubts as to its compatibility with the competitive market and thus declared compatible with the competitive market.
|